DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

DexCom (NASDAQ:DXCM) projected its annual revenue will climb toward $5.25 billion in 2026, marking a pivotal year for the glucose-monitoring leader as it phases out older hardware in favor of its ...

Today, I'm going to talk about clinical concerns that I think both our patients and we have been having about sensors. First of all, there was a recall of some of the Freestyle Libre 3 Plus devices, ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom CGM systems provide automatic blood glucose updates every five minutes. FreeStyle Libre sensors can last up to 15 days and no longer need frequent scanning for updates. Both Dexcom and ...

The Federal Circuit upheld an administrative tribunal’s decision to nix six claims from a DexCom Inc. patent covering implantable sensors used to monitor patients’ blood glucose levels. DexCom sued ...

Credit: Dexcom. The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required. In ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...